HIMS
T3Hims & Hers Health, Inc.
OverviewHims & Hers Health operates a multi-specialty telehealth platform delivering personalized treatments via licensed providers and ongoing care. Its revenue comes
Hims & Hers Health operates a multi-specialty telehealth platform delivering personalized treatments via licensed providers and ongoing care. Its revenue comes from US subscriptions across the Hims and Hers brands and a growing international footprint. In 2025, roughly 95% of revenue was US-based ($2.2B from Hims/Hers), with international (~$134M) expanding via ZAVA, Livewell and Eucalyptus.
- What They Do (Plain English & Analogies)
- Hims & Hers Health is a consumer-focused healthcare platform that connects people with clinicians, prescription medications, diagnostics and follow-up care through an app and web experience. Plain English: think of Hims & Hers as a digital clinic + pharmacy + lab that you subscribe to. Analogy: it's like Netflix for certain kinds of healthcare — a single app that curates treatments, refills prescriptions on a recurring basis, and delivers them to your door — but it also builds its own compounding and lab infrastructure so it can offer customized medicines and at-home testing. Another analogy: imagine a neighborhood primary care clinic, a specialty clinic (dermatology, sexual health, weight loss) and a diagnostic lab all rolled into one membership-focused digital product that emphasizes convenience, personalization and recurring care.
- Very Brief History
- Founded in 2017 to sell men's health products online (ED and hair loss), Hims rapidly expanded to a women's brand (Hers) and broadened into dermatology, sexual health and weight management. Public via SPAC in 2021, management pivoted from simple DTC product resale toward vertical integration: building >1M sq.ft. of compounding/pharmacy and lab operations, acquiring telehealth and diagnostic assets (Apostrophe, ZAVA, Livewell, YourBio) and signing to acquire Eucalyptus (2026). In 2024–2025 Hims accelerated into weight-loss (GLP-1s), whole-body labs, hormone therapies and international expansion.
- "Street Stereotype"
- On the Street HIMS is seen as a digital subscription health play that earlier looked like a marketing-led 'Instagram of pharmacies' but is now recasting itself as a vertically integrated telehealth platform. Investors are split: some view it as a high-growth, platform-driven healthcare disruptor; others see it as a GLP-1 / compounding–dependent story with regulatory and margin risks.
- Subsidiaries On Linked In*
- Hims & Hers (parent / consumer brands); Zava (Europe telehealth, acquired); Livewell (Canada, acquired); YourBio (at-home microneedle blood sampling, acquired/closed 2026); Eucalyptus (signed to be acquired, expands U.K./Australia/Japan footprint); Apostrophe (dermatology acquisition). Note: LinkedIn listings can show regional brands (Juniper was referenced as a women/weight brand in some markets) and localized brands under the Hims & Hers corporate umbrella.
- Customer Sectors & Example Clients
- Primary customers: individual consumers (direct-to-consumer subscribers) across wellness, sexual health, dermatology, weight loss, hormone therapy and preventive diagnostics. Secondary customers/partners: retail & wholesale partners for product distribution. Example partner / client companies (publicly referenced or logical partners): Target, Walmart, Walgreens, Amazon (wholesale/retail distribution channels historically referenced), telehealth/regulatory partners and API suppliers. Enterprise/partner relationships: pharma manufacturers (engagements/discussions with Novo Nordisk and other branded manufacturers for weight-loss drugs), diagnostic technology partners (YourBio, GRAIL discussions historically noted).
- New Customers / Segments They'Re Targeting
- - Consumers seeking proactive and preventive care via whole-body lab testing and remote diagnostics (people wanting at‑home biomarker monitoring). - People with hormonal conditions: low testosterone (men), perimenopause and menopause (women). - Weight-loss patients across a broader assortment of therapies (oral and injectable GLP‑1s and alternative metabolic/incretin treatments). - International consumers in markets added via acquisitions: U.K., Germany, France, Ireland, Spain, Canada, Australia, Japan. - Longevity/performance/recovery segments over time (peptides and other R&D programs).
- How Key Themes May Help/Hurt
- Help: - Verticalization & facility buildout (pharmacy/lab/503A capabilities) can reduce cost-to-serve, improve margin, ensure tighter quality control and enable lower-priced personalized medicines (advantage vs. third‑party compounding). - Diagnostics + YourBio at-home sampling can create a conversion flywheel: lab insights lead to treatment paths, increasing ARPU and retention. - AI and product investment can improve engagement, personalization and operational automation (lower support costs). - International acquisitions (Zava, Livewell, Eucalyptus) expand TAM and diversify revenue. Hurt: - Regulatory scrutiny of compounding (GLP‑1s) and shifting FDA positions could curtail compounded product sales or require costly compliance changes. - Heavy CapEx and integration costs for facilities and M&A could compress margins near term. - If branded manufacturers (Novo, Lilly) push direct-to-consumer channels or restrict supply, HIMS's compounding / distribution advantages could be weakened. - Rapid international growth may pressure margins while markets scale. Specific to 'motion-control' / automation buildout: investment in automation/robotics for compounding and fulfillment reduces per-unit cost and error rates (help) but requires significant CapEx, regulatory validation and operational change; automation failures or regulatory noncompliance could interrupt supply (hurt).
3 Main Long-Term Bull Details
- Verticalized, multi-specialty platform: owning compounding, pharmacy, labs and an integrated app creates a durable unit-economics advantage and cross-sell flywheel (higher LTV as subscribers adopt multiple personalized solutions). 2) Large TAM expansion and quick specialty rollouts: demonstrated rapid scale of weight‑loss and ability to bring new specialties (labs, menopause, low‑T) to >$100M run-rate quickly, signaling repeatable go‑to‑market capability across large underpenetrated categories. 3) International expansion via M&A: acquisitions (Zava, Livewell, Eucalyptus) + Canada entry provide fast access to millions of new consumers and the potential for $1B+ international revenue run-rate in a few years, diversifying revenue and growth drivers.
3 Main Long-Term Bear Details
- Regulatory & compounding risk: removal of compounding allowances for GLP‑1s or tightened rules would materially reduce high-ticket revenue and complicate the weight-loss offering. 2) Competitive pressure from branded pharma and deep-pocketed incumbents: manufacturers launching their own DTC channels (or preferential distribution) and large telehealth firms could compress HIMS's margin or market share. 3) Execution & capital intensity risks: heavy investments in facilities, international integrations and R&D (peptides) may take longer to pay off, compress margins and expose the company to cash/earnings volatility if speciality rollouts don't achieve expected economics.
- Competitors And Differentiation
- Competitors: Ro (Roman), Teladoc / Livongo (broad telehealth), Everlywell / LetsGetChecked / Quest (diagnostics), retail pharmacies (CVS/Walgreens), digital weight‑loss providers, pharma direct-to-consumer channels (e.g., LillyDirect) and regional telehealth players (Zava before acquisition). Differentiation: Hims & Hers emphasizes vertical integration (in‑house compounding and sterile fulfillment facilities), a subscription model with personalized daily regimens, rapid ability to add specialties, integrated diagnostics and data (labs + app), brand strength (Hims/Hers), and cross-selling across multiple specialties to increase retention and LTV. Strategy centers on combining scale, personalization and owned operational infrastructure to offer lower prices and faster access than many incumbents.
- Recent Performance & What The Market'S Focused On
- Recent performance (from the Feb 23, 2026 earnings call): 2025 revenue $2.35B (+59% y/y); Q4 2025 revenue $618M (+28% y/y). Subscribers exceeded 2.5M at year-end 2025; ~65% (≈1.6M) used personalized treatments. Adjusted EBITDA for 2025 was $318M (14% margin); full-year net income $128M; cash, short-term and long-term investments ~$929M at year-end. 2025 free cash flow was positive (~$57M after heavy investment). 2026 outlook: revenue $2.7–2.9B; adjusted EBITDA $300–375M; Q1 2026 guide $600–625M and adj. EBITDA $35–55M. Market focus / watch-list: regulatory exposure for compounded GLP‑1s and any FDA guidance changes; ability to secure branded supply partnerships (e.g., Novo Nordisk); growth and unit economics of new specialties (labs, menopause, low‑T); integration and ROI of acquisitions (Zava, Livewell, Eucalyptus); margin trajectory as investments in tech and international scale; and subscriber growth/retention metrics and ARPU trends (monthly revenue per average subscriber was $83 in Q4 2025, +11% y/y).
- Brands And Revenue Segments
- Primary brands: Hims (men's-focused offerings), Hers (women's-focused offerings), Juniper (market-specific women/weight brand referenced), Zava (Europe telehealth), Livewell (Canada), Eucalyptus (signed acquisition), YourBio (diagnostic technology). Revenue segments (management shifted to U.S. vs Rest-of-World): - U.S. revenue (domestic): >$2.2B in 2025 (the majority of total revenue). - International / Rest of World: $134M in 2025 (≈+400% y/y). Within U.S., management calls out Hims and Hers as primary brand buckets; Hers accounted for nearly 40% of U.S. revenue in 2025. Product / specialty breakdowns are operationally important but not fully disaggregated in call: weight loss (GLP‑1s and other metabolic therapies), sexual health (shift from on‑demand to daily personalized treatments), dermatology (hair and skin), labs/diagnostics, hormone therapies (low‑T, menopause), and wholesale/retail product revenue. Note: management previously reported weight-loss run‑rates and material revenue from traditionally tenured categories; non-GLP‑1 tenured specialties still generate the majority of revenue and cash flow.
Bull / Bear DetailsUpdated thesis (2026-02-25): Hims & Hers is rapidly morphing from a niche telehealth platform into a global, consumer-centric health ecosystem anchored by verti
Thesis
Updated thesis (2026-02-25): Hims & Hers is rapidly morphing from a niche telehealth platform into a global, consumer-centric health ecosystem anchored by verticalized labs, longevity offerings, and international expansion. A potential branded Wegovy supply arrangement with Novo Nordisk could de-risk GLP-1 exposure, while a scalable data-and-AI layer drives personalized care and higher LTV. Near-term margin pressure from infrastructure investments remains manageable amid a path to 2030 targets.
Bull case
Bull1: International expansion and acquisitions unlock durable growth. With ZAVA, Livewell, and the pending Eucalyptus deal, Hims & Hers targets over $1 billion in incremental international revenue and expects international break-even within 12-18 months post-close, broadening the platform beyond the U.S. and creating a multi-market, higher-powered revenue engine.
Bull2: Proactive care flywheel through diagnostics and personalized care. The Labs launch with 130+ biomarkers, YourBio home testing, and AI-driven test interpretation, enabling 70% of Labs customers to enter treatment plans and driving higher retention and LTV; scale of these new offerings targets multiple $100M run rates per specialty.
Bull3: Structural tech and AI advantage enabling faster time-to-market and stronger retention. The company's expanded tech and AI teams, 130 biomarkers, and at-home diagnostic devices support a unified platform where customers add, adjust, or switch treatments within a single app, driving higher engagement, conversion, and unit economics across multiples of offerings.
Bear case
Bear1: Near-term margin compression and execution risk from heavy investments in tech, AI, and new specialties, plus headwinds from weight-loss shipping cadence; margins may remain pressured as international expansion and R&D costs contribute to the P&L. If growth investments fail to yield scale, profitability could deteriorate versus expectations.
Bear2: Regulatory risk on GLP-1 compounding and potential loss of FDA shortage status; branded Wegovy partnership progress may not materialize, leaving GLP-1 exposure vulnerable to pricing pressure and competition, which could cap revenue growth in weight loss, delay profitability, and force a pivot to less scalable categories.
Bear3: International expansion risk remains material, with integration challenges, currency exposure, regulatory hurdles, and potential near-term margin drag in new markets even as break-even timelines compress; reliance on acquisitions to drive growth could backfire if expected synergies lag, or if post-close execution falters.
Bull / Bear Case
- Bear Case
- Near-term margin pressure from heavy investments in tech, AI, and new specialties, plus a weight-loss shipping cadence headwind that could damp revenue timing. GLP-1 regulatory risk looms if compounded approaches face headwinds or branded Wegovy supply delays, potentially constraining margin and growth. International expansion adds execution and currency risks, and the legacy sexual-health transition may damp near-term profitability. Valuation premiums reflect growth expectations that may not materialize if regulatory or competitive dynamics worsen.
- Bull Case
- Hims & Hers is evolving into a global, consumer-centric health platform beyond niche telehealth. Growth drivers include Hers expansion into menopause and dermatology, Labs and YourBio enabling proactive diagnostics with 130+ biomarkers, and rapid international expansion via ZAVA, Livewell and Eucalyptus. The platform leverages data-driven personalization, AI, and a scalable infrastructure to improve retention and Lifetime Value, while cash flow supports capex and accretive M&A. 2025 revenue reached $2.35B with adj. EBITDA of $318M; 2026 guidance implies continued growth to ~$2.7–$2.9B revenue and ~12% EBITDA, with international break-even potential and a push toward $6.5B revenue and $1.3B EBITDA by 2030 under a diversified, higher-margin mix.
- More Compelling & Why
- Bear; Valuation anchored to forward EV/EBITDA vs peers (HIMS trading at a high multiple given 2026E EBITDA). The strongest argument is near-term margin compression and GLP-1 regulatory risk that could erode upside; a flip would require a material branded Wegovy deal or international break-even and margin expansion in the mid-teens to unlock upside.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Eucalyptus closing and integration into the international footprint | Closing the Eucalyptus deal and integrating its operations is a one-time capitalization of international scale, turning a high-growth international expansion into a near-term profitability lever by accelerating revenue diversification and reducing domestic margin pressure. | Close of the Eucalyptus acquisition in 2H 2026; subsequent international break-even within 12–18 months after closing; progression of international revenue contribution toward the stated target of at least $200M in 2026 and beyond. | Bullish: Eucalyptus closes as expected and international segment starts moving toward break-even within the projected timeline; accelerates path to $6.5B revenue target. | Press releases and 8-K filings announcing closing and integration milestones; quarterly/annual investor presentations; 2026 guidance updates. | Google Trends: search interest for "Hims & Hers Eucalyptus" and related international expansion terms; media coverage volume. | Thinknum: media coverage and press release velocity on the Eucalyptus deal; AlphaSense: integration milestones and regulatory clearances. |
| Labs adoption strength and scale (Labs, menopause, low-T momentum) | Labs and related personalized care offerings are a core driver of long-term LTV and cross-sell across specialties; strong adoption validates the transition beyond GLP-1 dependence. | Labs engagement metrics: proportion of Labs customers eligible for treatment plans (target around 70%); conversion to treatment plans; progression to $100M+ run rate per new entry (Labs, menopause, low-T) within 12–24 months; 130 biomarkers in tests; 95% testosterone increases observed in early users. | Bullish: Labs-driven care conversion meets/exceeds 70% eligibility and ongoing scale toward $100M+ run rate; validates the platform's proactive care thesis. | Quarterly earnings disclosures and investor deck updates; lab/test utilization metrics in 2026 filings. | Google Trends for terms like "Hims Labs"; social sentiment around diagnostic testing; analyze press coverage of the Labs launch. | Thinknum: volume of lab test orders or platform engagement metrics; CBInsights/Trends for diagnostics adoption signals. |
| Canada launch and ongoing international expansion with target >$200M international rev; break-even timeline | Canada launch marks tangible international footprint growth; international expansion is a major growth vector with substantial long-term margin implications as scale improves. | Announcement date for Canada launch; incremental international revenue contribution through U.K., Germany, France, Ireland, Spain, Canada; progress toward international break-even 12–18 months post-Eucalyptus closing; 2026 guidance for international revenue contribution. | Bullish: Canada launch occurs as planned and international revenue approaches the $200M baseline; international segment moves toward profitability as scale compounds. | Company press releases, investor presentations, and 10-K/10-Q filings; quarterly international revenue breakdown in earnings releases. | Google Trends: search interest in Canada market expansion and brand terms; regulatory updates on international markets. | Thinknum: international revenue proxies by region; web traffic to international landing pages; Joule/Market data providers with regional revenue estimates. |
| Potential branded Wegovy ( Novo Nordisk) availability on platform | A branded Wegovy offering would broaden GLP-1 access with potentially better margins and supply reliability, reducing regulatory risks tied to compounded formulations. | Public announcements of branded Wegovy availability on the platform or formal supply agreements with Novo Nordisk; progress updates from management on branded GLP-1 strategy. | Bullish: Clear progress toward branded Wegovy on platform; improved supply/sustainability offsetting GLP-1 compounding risks. | 8-K filings, press releases, investor presentations; Novo Nordisk regulatory/partner announcements. | Google Trends for "Wegovy on Hims & Hers" and related terms; media coverage volumes. | Thinknum: monitoring partner announcements and branded product mentions; Bloomberg/Thomson Reuters regulatory/news feeds. |
| Q1 2026 weight-loss shipping cadence headwind (~$65M revenue impact) | A real revenue headwind tied to the transition to 503A fulfillment with shipping cadence changes can materially impact Q1 profitability and set the trajectory for early 2026 margins. | Actual Q1 2026 revenue, the magnitude of the weight-loss shipping headwind and whether the headwind abates in subsequent quarters; maintenance of overall demand and customer engagement. | Bearish: If the $65M headwind is realized and persists, pressuring near-term revenue and EBITDA; potential risk to margin trajectory in 2026. | Q1 2026 earnings release and accompanying 10-Q; investor presentations; company guidance updates. | Company press releases and earnings call transcripts; regulatory filings noting shipping/fulfillment changes. | FactSet/Refinitiv earnings data feeds; AlphaSense monitoring of supply-chain related disclosures. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Monthly Revenue per Average Subscriber | ARPU reflects monetization strength and cross-segment potential as new offerings (Labs, menopause, low-T) scale; sustained ARPU growth supports higher LTV and margin resilience during ongoing investments. | 11% |
| International Revenue | International expansion is a key growth vector driven by ZAVA, Livewell and Eucalyptus; international contribution tests model viability and margin trajectory as the company aims for meaningful scale beyond the U.S. in 2026. | ~400% |
| Total Revenue | Total Revenue remains the primary indicator of platform scale and durable growth across U.S. and international markets, including non-GLP-1 offerings; Q4 2025 momentum sets the stage for 2026 execution and potential margin expansion as scale improves. | 28% |
Key QuestionsWill Hims & Hers meet its 2026 guidance in light of a roughly $65 million Q1 weight-loss shipping headwind and a recent large-brand marketing spend, specificall
Will Hims & Hers meet its 2026 guidance in light of a roughly $65 million Q1 weight-loss shipping headwind and a recent large-brand marketing spend, specifically can Q1 revenue hit $600–$625 million and the full-year revenue and Adjusted EBITDA targets of $2.7–$2.9 billion and $300–$375 million respectively?
- Question 2
Will the international expansion through Eucalyptus, ZAVA, and Livewell deliver international break-even within 12–18 months after close and generate at least $200 million of annual international revenue in 2026 to support the company's 2030 targets?
- Question 3
Is the diversification beyond GLP-1s into Labs, menopause and low-T, plus the potential branded Wegovy partnership with Novo Nordisk, sufficient to sustain growth and improve margins if GLP-1 volatility persists?
Rerating Thresholds
| Metric | What'S Needed For Rerating | Why It Matters | Earnings Date |
|---|---|---|---|
| Subscribers | Total subscriber growth must re-accelerate to 48-50% y/y, effectively reversing the deceleration to 20% seen in late 2025. Specifically, 'Subscribers using Personalized Solutions' needs to exceed 55% y/y growth, and the percentage of the total base using personalized treatments must cross a 55% threshold to prove the platform's 'moat' is expanding beyond generic offerings. | Personalized subscriber growth is the primary driver of higher LTV and retention. Hitting 50%+ growth proves the 'proactive health' pivot (diagnostics and longevity) is successfully offsetting legacy sexual health headwinds and de-risks the stock from binary regulatory outcomes regarding GLP-1 compounding, justifying a return to a premium growth multiple. | 2026-02-23 |
| Total Revenue | HIMS needs to deliver quarterly revenue exceeding $515M (representing ~40% YoY growth), significantly beating the management guidance of 26-30%. Additionally, the company must issue FY2026 revenue guidance of $2.1B or higher, signaling that the 'Hers' brand is accelerating toward its $1B target and that the diagnostic/longevity launches are successfully diversifying revenue away from the volatile GLP-1 compounding segment. | A significant revenue beat and raised guidance would dismantle the 'revenue cliff' thesis tied to the FDA's GLP-1 shortage list. It proves that strategic price cuts and vertical integration are driving sustainable volume growth, restoring investor confidence in HIMS's transition from a niche telehealth provider to a durable, high-growth proactive health platform. | 2026-02-23 |
| Adjusted EBITDA | To rerate higher, HIMS needs to deliver an Adjusted EBITDA margin of 12% or higher for the quarter, significantly beating its 10% guidance, while maintaining YoY EBITDA growth above 150% (relative to the current 315% baseline). Crucially, management must provide FY 2026 Adjusted EBITDA guidance in the $260M–$280M range, signaling a return to a 13-15% margin profile. This would demonstrate that the 'temporary pause' in expansion is over and that vertical integration is successfully offsetting the impact of strategic GLP-1 price cuts. | This threshold is vital to prove the sustainability of HIMS' business model amidst GLP-1 pricing pressure and regulatory uncertainty. Hitting these numbers confirms that verticalization provides a structural cost advantage, allowing HIMS to underprice competitors while expanding margins. This de-risks the 'value trap' narrative and validates the path toward their $1.3B 2030 EBITDA target. | 2026-02-23 |
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1) Diagnostics and devices innovation to expand the health platform (Labs, YourBio, wearables integration). 2) AI as a critical layer to personalize care and scale operations (data, AI tools, proactive messaging). 3) Deeper data and more proactive, personalized treatments, plus international expansion and category diversification to reach 2030 targets. | The call framed Hims & Hers as aggressively evolving into a global, consumer-centric proactive health platform. Near-term margin pressures and some revenue timing headwinds exist from shipping cadence changes and category transitions, but management conveyed confidence in leveraging a strong balance sheet and strategic investments to drive long-term growth and a path to 2030 targets. Tone: confident and ambitious. | Hims US: >40% YoY in Q3 2025; Hers US: triple-digit YoY in Q3 2025; International: not disclosed in Q3 2025 transcript. | 1) GLP-1 regulatory risk and potential branded Wegovy partnership with Novo Nordisk; mgmt response: pursuing branded Wegovy alongside compounded options and leveraging verticalization to lower prices while aiming to preserve long-term margins. 2) Margin expansion pause due to investments in technology and infrastructure; mgmt response: these investments are high-ROI and expected to drive future growth and free cash flow. 3) Durability of growth and mix shift away from GLP-1 toward Labs, menopause, low testosterone and other offerings; mgmt response: diversification strategy supported by labs/menopause/low-T and international expansion to sustain growth and LTV. | U.S. Hims revenue growth: over 30% YoY in 2025; U.S. Hers revenue growth: triple-digit YoY in 2025; International revenue growth: almost 400% YoY in 2025 to $134 million. |
· 2025Q3 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Verticalization and Infrastructure: Expanding facility footprint to over 1 million square feet to support internal 503A sterile compounding, which management believes establishes a 'gold standard' for safety and allows for price reductions in GLP-1 and testosterone treatments. 2. Proactive Health and Diagnostics: Launching whole-body lab testing by year-end 2025 and a Longevity specialty in 2026 to shift the platform from reactive treatment of conditions to proactive health management. 3. Global Scale: Integrating the Zava acquisition to reach 200 million adults in Europe and preparing for a Canada launch in 2026, targeting a $1 billion+ international revenue opportunity. | The takeaway is that Hims & Hers is aggressively evolving from a telehealth provider for specific conditions into a vertically integrated, global 'proactive health' platform. While the company is facing near-term margin pressure and revenue headwinds from shipping cadence changes and segment transitions, management is 'leaning in' to its $1.1 billion cash position to fund massive expansion in diagnostics and longevity. The tone was extremely confident and ambitious, characterized by a 'build the future' mentality. | In Q2 2025, Total Revenue grew 52% y/y (indicating a slight deceleration to 49% in Q3). Subscriber growth in Q2 2025 was 43% y/y (decelerating to 20% y/y in Q3, though management highlighted specific segment strengths). | 1. GLP-1 Strategy and Novo Nordisk Partnership: Analysts questioned the impact of price cuts and the status of discussions with Novo Nordisk. Management responded that they are in active discussions to offer branded Wegovy alongside compounded options and that verticalization allows them to lower prices while maintaining long-term margin targets. 2. Margin Compression and Investment: Analysts pressed on the 'temporary pause' in margin expansion due to increased spending. Management explained that heavy investments in tech talent, AI-assisted tools, and infrastructure are high-ROI initiatives that will drive the next phase of growth and long-term free cash flow. 3. Core Business Growth Deceleration: Analysts asked about slowing growth in legacy segments like sexual health. Management responded that they are intentionally transitioning users from generic on-demand solutions to personalized daily treatments, which creates a short-term headwind but will lead to more durable recurring growth and acceleration in H2 2026. | Total Revenue: 49% y/y growth; Hers Brand: Near or above triple-digit y/y growth; Hims Brand (Subscribers): >40% y/y growth when excluding the sexual health transition impact; Weight Loss Specialty: On track for >$725M in 2025 revenue. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Expanding TAM via new specialties (low testosterone, menopause, Labs) and rapid geographic expansion (Canada; U.K., Germany, France, Ireland, Spain; Australia and Japan via Eucalyptus; ZAVA and Livewell acquisitions) with 2.5M+ subscribers; 130+ biomarkers; aim for >$1B incremental international revenue in 3 years. | Scalability and vertical integration as a moat; price reductions on GLP-1 to improve access and margins; active discussions with Novo Nordisk to offer branded Wegovy on the platform; potential regulatory scrutiny of GLP-1 compounding; competition from traditional providers as the platform expands into diagnostics and longevity. | Industry shifting from reactive treatment to proactive, preventative care; diagnostics and wearables integration; AI as a critical layer; mass-market at-home testing and data-driven personalization are becoming core to health platforms. | Long-term targets include $6.5B revenue and $1.3B adjusted EBITDA by 2030; international business expected to break even within 12–18 months after Eucalyptus closing; 2026 guidance for revenue and EBITDA; labs, testosterone, menopause and AI-enabled platform experiences to scale with ongoing international expansion. | Premium | Proactive Longevity & Diagnostics: broad shift to accessible, mass-market health diagnostics and proactive care across life stages. | "The opportunity is significant."; "Hers brand is on pace to deliver revenue of over $1 billion in 2026."; "Active discussions with Novo Nordisk to make Wegovy injections available through our platform."; "In just 90 days, we created 3 distinct new entry points to our platform." | "Gross margins declined approximately 2 points quarter-over-quarter to 72%."; "Headwinds in the fourth quarter from shorter shipment cadences."; "Approximately $65 million revenue headwind in Q1 2026 from shipping cadences in weight loss." | Investments in technology and AI talent, safety/compliance staffing, and leadership hires; international headcount growth and expansion of facilities to over 1 million square feet; notable marketing spend such as the 60-second Super Bowl ad as part of brand education. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Hims & Hers is aggressively expanding its TAM through new specialties including low testosterone, perimenopause, and menopause. The company is launching comprehensive whole-body lab testing before year-end 2025 and a longevity specialty in 2026. Geographically, they are expanding into Canada (targeting 2/3 of adults who are overweight) and leveraging the Zava acquisition to reach 200 million adults across the U.K., Germany, France, Ireland, and Spain. They are also in active discussions with Novo Nordisk to offer Wegovy and oral semaglutide. | The company views its scale as a primary competitive advantage, allowing it to act as a 'powerful curator' of health solutions. They are positioning themselves against traditional providers by offering personalized, high-touch care that is often stigmatized or hard to access. To maintain a leadership position in weight loss, they strategically reduced compounded GLP-1 prices by up to 20%. They are also preparing for the 2026 entry of generic semaglutide by engaging with leading generic manufacturers. | The industry is shifting from reactive treatment of existing conditions to proactive, preventative health management. There is a significant gap in specialized care, noted by the fact that only 30% of OB/GYN residency programs offer formal training on menopause. The company also highlights a 'green list' of FDA-registered GLP-1 API suppliers, signaling a tightening of regulatory and quality standards in the compounding space. | HIMS is tracking toward its 2030 goal of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. The Hers brand is expected to reach $1 billion in annual revenue by 2026. The company is transitioning its sexual health business from on-demand generics to daily personalized treatments, a shift expected to normalize by late 2026. Future growth will be driven by 'verticalizing' sterile compounding infrastructure and integrating AI-assisted tools like nutritional coaches. | Premium | Proactive Longevity & Diagnostics: A shift toward 'the great equalization' of high-end diagnostics, moving from $5,000+ boutique testing to affordable, mass-market whole-body screening for early detection of cancer and cardiovascular disease. | "Subscribers using personalized solutions grew 50% year-over-year."; "Hers brand... on pace to deliver revenue of over $1 billion in 2026."; "Active discussions with Novo Nordisk to make Wegovy injections... available through our platform."; "Marketing as a percentage of revenue was 39%, representing more than 6 points of leverage." | "Gross margins declined over 2 points quarter-over-quarter to 74%."; "Headwinds in the fourth quarter from shorter shipment cadences."; "Temporary pause in year-over-year margin expansion."; "Continued moderation in our on-demand sexual health business." |
Earnings ResultsQ4'25 revenue clearly missed the quarterly threshold of ~40% YoY growth, totaling $618M with 28% YoY growth. However, the company did provide robust full-year g
| Metric | Prior Quarter | Rerating Trigger | Actual Reported | Hit Target? | Notes |
|---|---|---|---|---|---|
| Total Revenue | 77% | HIMS needs to deliver quarterly revenue exceeding $515M (representing ~40% YoY growth), significantly beating the management guidance of 26-30%. Additionally, the company must issue FY2026 revenue guidance of $2.1B or higher, signaling that the 'Hers' brand is accelerating toward its $1B target and that the diagnostic/longevity launches are successfully diversifying revenue away from the volatile GLP-1 compounding segment. | $618 million (28% y/y growth) | Partially | Q4'25 revenue clearly missed the quarterly threshold of ~40% YoY growth, totaling $618M with 28% YoY growth. However, the company did provide robust full-year guidance for 2026 ($2.7–$2.9B revenue), well above the $2.1B minimum stated in the threshold. The stock price reaction to quarterly results isn't explicitly provided in the transcript, but management emphasized durable multi-year growth and international expansion as positives despite near-term headwinds. |
| Subscribers | 44% | Total subscriber growth must re-accelerate to 48-50% y/y, effectively reversing the deceleration to 20% seen in late 2025. Specifically, 'Subscribers using Personalized Solutions' needs to exceed 55% y/y growth, and the percentage of the total base using personalized treatments must cross a 55% threshold to prove the platform's 'moat' is expanding beyond generic offerings. | Not disclosed in transcript (4Q25 subscriber YoY growth not provided) | No | While the company reported over 2.5 million subscribers by end-2025 and highlighted growth in various segments, the transcript did not specify the quarterly YoY subscriber growth rate. Given a prior-quarter (Q3 2025) YoY subscriber growth of 44% and the target of 48-50%, there is no evidence in the transcript that the required acceleration occurred in 4Q25. |
| Adjusted EBITDA | 315% | To rerate higher, HIMS needs to deliver an Adjusted EBITDA margin of 12% or higher for the quarter, significantly beating its 10% guidance, while maintaining YoY EBITDA growth above 150% (relative to the current 315% baseline). Crucially, management must provide FY 2026 Adjusted EBITDA guidance in the $260M–$280M range, signaling a return to a 13-15% margin profile. This would demonstrate that the 'temporary pause' in expansion is over and that vertical integration is successfully offsetting the impact of strategic GLP-1 price cuts. | 11% Adjusted EBITDA margin (Q4'25); $66 million Adjusted EBITDA | No | Q4'25 Adjusted EBITDA margin of 11% misses the 12% threshold. The company did report strong full-year EBITDA growth and guided $300–$375M for 2026, indicating margin expansion is expected longer term, but not in the single quarter's result. The transcript does not provide a stated QoQ or YoY margin change for the quarter, limiting confirmation of a 12%+ quarter margin from this release. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-23 | Hims & Hers reported Q4 revenue of $618M (up 28% YoY) and full-year revenue of $2.35B, guiding 2026 revenue of $2.7-2.9B with adjusted EBITDA of $300-375M. Growth drivers include Labs, menopause, low-T and faster international expansion. The market reacted modestly negative: stock -0.32% on earnings day, underperforming SPY, suggesting skepticism about GLP-1 exposure and near-term margins despite a clear long-term platform pivot to proactive care and 2030 targets. | Other | Neutral | https://investors.hims.com/news-releases/news-release-details/hims-hers-health-reports-fourth-quarter-and-full-year-2025-earnings | False | -0.32% (vs SPY: -1.05%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| HIMS_1e455609 | second half of this year | 2026-07-01 | 2026-12-31 | Signed acquisition of Eucalyptus — closing of the Eucalyptus transaction. | Closing materially expands Hims & Hers' international footprint (UK/Europe, Australia, Japan), requires upfront ~ $240M cash at close and up to $1.15B total consideration, and could materially change 2026 revenue mix, cash use, and near-term adjusted EBITDA given integration costs and expected revenue contributions. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_27d621bf | second half of this year | 2026-07-01 | 2026-12-31 | Management expectation that Eucalyptus will contribute at least $200 million of incremental revenue in H2 2026 upon closing. | If realized, this would meaningfully boost 2H26 and full-year international revenue, alter guidance realization and investor perception; failure to realize these contributions (due to delayed close or weaker performance) would weaken FY26 revenue and international growth assumptions. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_8ce0db05 | within 12 to 18 months | 2027-02-23 | 2027-08-23 | Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months. | Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_b020aa58 | next few years | 2026-02-23 | 2028-02-23 | Ongoing regulatory and legal scrutiny of compounded GLP-1s (FDA/DOJ engagement and potential restrictions or changes to compounding policy, including removal from shortage lists or bans on certain compounded semaglutide products). | A regulatory restriction or ban on compounded GLP-1s would remove a high-ticket, fast-growing revenue stream and could materially compress revenue and adjusted EBITDA; conversely, a favorable regulatory outcome or secured branded supply partnerships would de-risk weight-loss revenue and support guidance — the outcome affects demand, pricing, and supply strategy. | Theme | 2026-02-23 | earnings_transcript |
| HIMS_b6863bc9 | first quarter of 2026 | 2026-01-01 | 2026-03-31 | Revenue timing/headwind from the change in shipping cadence to 503(a) fulfillment in the weight-loss business, which management estimates will reduce Q1 revenue by approximately $65 million. | This operational timing change compresses Q1 2026 revenue (a material near-term impact on reported growth) and could influence investor sentiment and quarterly comparisons even though management says it is timing-related rather than demand-driven. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_d445390e | throughout 2026 | 2026-01-01 | 2026-12-31 | Scaling of newer offerings (labs, low testosterone support, menopausal support) with management's view that each can 'eclipse $100 million in annual revenue' and will incrementally scale over the year. | If these specialties reach $100M run-rates they would materially diversify revenue away from GLP-1 dependence, improve retention and margins long-term; failure to scale as expected would leave the company more exposed to weight-loss/regulatory risk and pressure on growth assumptions. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_7a775872 | in 2026 | 2026-01-01 | 2026-12-31 | Integration and scaling of YourBio's microneedle at‑home blood-sampling technology into Hims & Hers' Labs offering (post-close integration to enable at‑home diagnostics). | Successful integration could accelerate Labs adoption, increase addressable market and data-driven personalization (raising LTV and cross-sell), while delays or poor execution would slow diagnostic-led growth and reduce anticipated unit-economics improvements. | Ticker | 2026-02-23 | earnings_transcript |